BioSight
Companies
OMEROS CORP logo

OMER

NASDAQSEATTLE, WA
OMEROS CORP

Omeros Corporation discovers and develops protein and small-molecule drugs targeting complement-mediated diseases, cancers, and neurological disorders, with a focus on inhibiting specific complement pathway enzymes (MASP-2 and MASP-3). The company is at a commercial stage with YARTEMLA (narsoplimab-wuug), its first FDA-approved product for hematopoietic stem cell transplant-associated thrombotic microangiopathy, which began sales in January 2026. Omeros has also submitted a marketing application for YARTEMLA in Europe and is developing additional complement-targeted candidates.

Price history not yet available for OMER.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar